November 30, 2016 - By Peter Erickson
Daniel Getman, an insider and also director of the exchange-traded company Sucampo Pharmaceuticals Inc made deal. He sold 20,000 shares of the firm with Daniel Getman’s stock sale worth approx. $337,268 US Dollars – calculated based on $16.9 a share. The deal was dated 30-11-2016 and was unveiled in a document filed with the (SEC). The document is ready for review here.
Out of 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $31 is the highest target while $14 is the lowest. The $22.75 average target is 40.09% above today’s ($16.24) stock price. Sucampo Pharma has been the topic of 21 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Mizuho upgraded the stock to “Buy” rating in Wednesday, April 20 report. Maxim Group maintained the stock with “Buy” rating in Wednesday, August 26 report. WallachBeth Capital maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Thursday, August 6. WallachBeth Capital has “Hold” rating and $24 price target. The firm has “Neutral” rating given on Friday, November 13 by Mizuho. The firm has “Outperform” rating given on Wednesday, September 7 by Northland Capital. The firm has “Mkt Perform” rating by Leerink Swann given on Thursday, September 3. The company was reinitiated on Thursday, October 29 by TH Capital. The stock has “Hold” rating given by WallachBeth Capital on Thursday, August 27. On Monday, January 18 the stock rating was maintained by Mizuho with “Neutral”. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Neutral” rating given on Thursday, August 4 by Mizuho.
Insitutional Activity: The institutional sentiment is 0.98 in 2016 Q2. Its the same as in 2016Q1. The ratio is without change, as 17 funds sold all Sucampo Pharmaceuticals, Inc. shares owned while 46 reduced positions. only 22 funds bought stakes while 40 increased positions. They now own 17.83 million shares or 12.41% less from 20.36 million shares in 2016Q1.
Northern Trust reported 292,392 shares or 0% of all its holdings. Employees Retirement Association Of Colorado accumulated 0% or 8,353 shares. Jpmorgan Chase owns 31 shares or 0% of their US portfolio. The Massachusetts-based Massachusetts Svcs Ma has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Renaissance Tech Ltd Company holds 1.11 million shares or 0.02% of its portfolio. The New York-based Qs Ltd Co has invested 0.01% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Secor Capital Ltd Partnership, a New York-based fund reported 68,688 shares. Invesco Ltd, a Georgia-based fund reported 118,153 shares. Financial Bank Of Mellon Corp has invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Panagora Asset Mgmt has invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). State Street Corporation accumulated 427,527 shares or 0% of the stock. Tradewinds Glob Invsts Limited Co last reported 0.02% of its portfolio in the stock. Ladenburg Thalmann Svcs holds 100 shares or 0% of its portfolio. Loomis Sayles And Communications Lp holds 124 shares or 0% of its portfolio. Glenmede Trust Communication Na accumulated 331 shares or 0% of the stock.
Insider Transactions: Since November 15, 2016, the stock had 0 buys, and 2 insider sales for $2.43 million net activity. The insider Alder Matthias sold 150,000 shares worth $2.40 million. Another trade for 1,766 shares valued at $27,514 was made by Smith Andrew P on Tuesday, November 15.
About 809,320 shares traded hands or 65.53% up from the average. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has risen 56.48% since April 27, 2016 and is uptrending. It has outperformed by 51.25% the S&P500.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $790.97 million. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. It has a 54.62 P/E ratio. It operates through development and commercialization of pharmaceutical products segment.
According to Zacks Investment Research, “Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.”
Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on March, 14. They expect $0.44 earnings per share, 0.00% or $0.00 from last year’s $0.44 per share. SCMP’s profit will be $21.43M for 9.23 P/E if the $0.44 EPS becomes a reality. After $0.28 actual earnings per share reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 57.14% EPS growth.
Another recent and important Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news was published by Bizjournals.com which published an article titled: “Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million” on January 11, 2016.
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a biopharmaceutical company. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. The Firm operates through development and commercialization of pharmaceutical products segment. The Company’s activities are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts activities in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.